BioNTech acquires T cell therapy-focused Neon for $67m
BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18 per share or approximately $67m. According to...
Focus:
-
BioNTechMergers & Acquisitions$67M
-
MerckMergers & Acquisitions$2.7BN
-
IncyteLicensing Agreement$900M
-
NeuroBo PharmaceuticalsMergers & AcquisitionsUndisclosed
-
LillyMergers & Acquisitions$1.1BN
-
PfizerPartnership$150M
-
Altavant SciencesMergers & AcquisitionsUndisclosed
-
AlmirallMergers & Acquisitions$15M
-
GalenMergers & AcquisitionsUndisclosed
-
MerckLicensing Agreement$50M
-
BeiGenePartnershipUndisclosed
-
BioconMergers & Acquisitions$100M
-
AstraZenecaLicensing Agreement$181M
-
Global Blood TherapeuticsPartnership$375M
-
FreelineCapital Raising$80M
-
CytoDynLicensing Agreement$87.5M
-
CRUKLicensing AgreementUndisclosed
-
Charles River LaboratoriesMergers & Acquisitions$380M
-
RocheMergers & Acquisitions$4.8BN
-
Promethera BiosciencesCapital Raising$52.47M
-
AlmirallPartnershipUndisclosed
-
NovartisLicensing AgreementUndisclosed
-
SanofiPartnershipUndisclosed
-
Amneal PharmaceuticalsMergers & Acquisitions$340M
-
AbbViePartnershipUndisclosed
-
MerckMergers & Acquisitions$2.7BN
-
Boehringer IngelheimPartnershipUndisclosed
-
SanofiMergers & Acquisitions$2.5BN
-
Janssen BiotechLicensing Agreement$750M
-
Vedanta BiosciencesPartnership$5.8M
-
![]()
Merck closes $2.7bn acquisition of biopharmaceutical firm ArQule
-
![MorphoSys Incyte B cell deal]()
MorphoSys and Incyte sign $900m deal for B-cell malignancies drug
-
![Lilly to acquire Dermira]()
Lilly to acquire Dermira for approximately $1.1bn
-
![Pfizer oncology eFFECTOR]()
Pfizer signs oncology agreement with STR-focused eFFECTOR
-
![]()
Merck collaborates on small molecule inhibitors with Taiho and Astex
-
![AstraZeneca sells Arimidex and Casodex rights]()
AstraZeneca sells Arimidex and Casodex rights for $181m
Submit a deal
Ensure your company's deals are accurately presented to thousands of potential clients by using our deals submission form.
DEALS ANALYSIS
Vertex-Semma $950m acquisition: bringing diabetes into the pipeline
Vertex Pharmaceutics has announced it has entered into a definitive agreement to acquire Semma Therapeutics for $950m. Semma is an early-stage biotech that is developing stem cell therapies for type...
Takeda-Shire deal: the strategy behind Japan’s largest foreign acquisition
Only eight months after the acceptance of its offer, Japanese pharma company Takeda completed its acquisition of international biotech Shire in January 2019.
US pharma industry sees a drop of 22.2% in deal activity in July 2019
The US pharma industry saw a drop of 22.2% in overall deal activity during July 2019, when compared with the last 12-month average, according to GlobalData's deals database.
Pharma industry deals in July 2019 total $4.57bn globally
Total pharma industry deals for July 2019 worth $4.57bn were announced globally, according to GlobalData's deals database.
Deals interview with Mike Preston of Cleary Gottlieb: Oncology is driving healthcare M&As
Total pharma industry M&A deals in Q2 2019 worth $114.8bn were announced globally, according to GlobalData’s deals database.
China’s pharma industry sees a drop of 28.1% in deal activity in Q2 2019
China's pharma industry saw a drop of 28.1% in overall deal activity during Q2 2019, when compared with the last four-quarter average, according to GlobalData's deals database.
North America’s pharma industry sees a drop of 10.3% in deal activity in Q2 2019
North America's pharma industry saw a drop of 10.3% in overall deal activity during Q2 2019, when compared to the four-quarter average, according to GlobalData's deals database.
Europe’s pharma industry sees a rise of 1.2% in deal activity in Q2 2019
Europe's pharma industry saw a rise of 1.2% in overall deal activity during Q2 2019, when compared to the four-quarter average, according to GlobalData's deals database.
Pharma industry M&A deals in Q2 2019 total $114.8bn globally
Total pharma industry M&A deals in Q2 2019 worth $114.8bn were announced globally, according to GlobalData's deals database.
Pharma industry venture financing deals in Q2 2019 total $2.72bn in US
Total pharma industry venture financing deals in Q2 2019 worth $2.72bn were announced in the US, according to GlobalData's deals database.
DEALS NEWS
Close
Close
Close
Go Top
